GlassScriptPhysician profile
Taylor J Atchley
NPI 1972923860
$3,552.07
in general payments reported to CMS, 2019-2025
20 companies · $1,810 in 2025
The $1,810 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $28.75 · 2023: $424 · 2024: $1,289 · 2025: $1,810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,488 · Education: $34.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,488.34 |
| Education | $34.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,045.71 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $720.70 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $580.95 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $308.72 | 2024-2025 | |
| Csl Behring | $170.40 | 2023-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $170.12 | 2023-2024 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $106.69 | 2024-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $96.77 | 2023-2025 | Takhzyro, Hyqvia |
| Biocryst US Sales Co., LLC | $62.57 | 2023-2025 | Orladeyo |
| Cycle Pharmaceuticals INC | $46.43 | 2025 | Sajazir |
| Amgen INC. | $42.87 | 2024-2025 | Tezspire |
| Pharming Healthcare, INC. | $31.38 | 2024 | Ruconest |
| Pfizer INC. | $29.82 | 2025 | |
| Aimmune Therapeutics, INC. | $25.26 | 2023 | |
| X4 Pharmaceuticals, INC. | $24.30 | 2025 | Xolremdi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $21.83 | 2025 | Dawnzera |
| Sanofi Pasteur INC. | $20.78 | 2025 | |
| Galderma Laboratories, L.P. | $18.35 | 2025 | Nemluvio |
| Optinose US, INC. | $14.67 | 2024 | |
| Merck Sharp & Dohme LLC | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Atchley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.